Association of Serum ELMO-3 Levels with Metastatic Status and Survival Outcomes in Non-Small Cell Lung Cancer
Current Issues in Molecular Biology · 21.04.2026 · 48 (4) · 427
DOI: 10.3390/cimb48040427 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 21.04.2026. Verfasst von Hilal Oğuz Soydinç und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul University.
Abstract (Originalsprache)
Non-small cell lung cancer remains one of the leading causes of cancer-related mortality worldwide, and identifying molecular markers associated with tumor progression and metastasis is important for improving patient management. This study investigated serum ELMO-3 levels in patients with NSCLC and evaluated their relationship with clinicopathological characteristics. Serum samples from 50 NSCLC patients and 20 healthy controls were analyzed. ELMO-3 concentrations were measured using an enzyme-linked immunosorbent assay. Statistical analyses included non-parametric group comparisons, receiver operating characteristic curve analysis, Kaplan–Meier survival analysis, and multivariate Cox proportional hazards regression. The mean ELMO-3 level was 0.409 ± 0.543, which was used as the cutoff value to categorize patients into low- and high-ELMO-3 groups; 76% of patients were classified as low-ELMO-3 and 24% as high-ELMO-3. The results showed that serum ELMO-3 levels did not differ significantly between NSCLC patients and healthy controls and were not associated with metastatic status. However, a significant association was observed between ELMO-3 expression status and tumor histopathology. Survival analysis demonstrated that distant metastasis and radiotherapy were significantly associated with overall survival. In multivariate analysis, age, operability, distant metastasis, and serum ELMO-3 levels were identified as independent factors associated with survival. These findings suggest that circulating ELMO-3 may have potential prognostic relevance; however, the results should be interpreted with caution and require validation in larger, independent cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Basic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.
- Department of Clinic Oncology, Oncology Institute, Istanbul University, 34093 Istanbul, Türkiye.
ORCID-Profile: Hilal Oğuz Soydinç, Murat Serilmez, Ceren Tilgen Yasasever, Elif Bilgin Doğru, Uğur Gezer
Förderung
- Istanbul University
Zitieren
APA
Oğuz Soydinç, H., Serilmez, M., Tilgen Yasasever, C., Bilgin Doğru, E., Gezer, U., Karaman, Ş., Sakin, N. D., & Duranyıldız, D. (2026). Association of Serum ELMO-3 Levels with Metastatic Status and Survival Outcomes in Non-Small Cell Lung Cancer. Current Issues in Molecular Biology, 48(4), 427. https://doi.org/10.3390/cimb48040427
Vancouver
Oğuz Soydinç H, Serilmez M, Tilgen Yasasever C, Bilgin Doğru E, Gezer U, Karaman Ş, et al. Association of Serum ELMO-3 Levels with Metastatic Status and Survival Outcomes in Non-Small Cell Lung Cancer. Current Issues in Molecular Biology. 2026;48(4):427. doi:10.3390/cimb48040427
BibTeX
@article{OuzSoydin2026,
author = {Oğuz Soydinç, Hilal and Serilmez, Murat and Tilgen Yasasever, Ceren and Bilgin Doğru, Elif and Gezer, Uğur and Karaman, Şule and Sakin, Nergiz Dağoğlu and Duranyıldız, Derya},
title = {Association of Serum ELMO-3 Levels with Metastatic Status and Survival Outcomes in Non-Small Cell Lung Cancer},
journal = {Current Issues in Molecular Biology},
year = {2026},
volume = {48},
number = {4},
pages = {427},
doi = {10.3390/cimb48040427}
}
EUVIMED